Could a bone drug help women with anorexia? new study investigates
NCT ID NCT04779216
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether romosozumab, a drug that builds bone, can improve bone density in women with anorexia nervosa. Thirty women received either romosozumab or a placebo for 12 months, followed by a single dose of zoledronic acid. The goal was to see if bone density and structure improved, offering a potential way to prevent fractures in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
romosozumab (a bone-building drug) and zoledronic acid (a bone-strengthening drug)
What this could lead to
If successful, this could point toward a treatment to improve bone density and reduce fracture risk in women with anorexia nervosa.
What could go wrong
This is a small pilot study with only 30 participants, so results may not apply to everyone. The long-term benefits and risks are still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANOREXIA NERVOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States